LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

Home・Aandelen Lijst・Cassava Sciences Inc

Cassava Sciences Inc

Open

SectorGezondheidszorg

3.25 1.88

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.12

Max

3.25

Belangrijke statistieken
By Trading Economics
Inkomsten	33M -11M
Verkoop	840K 840K
EPS	-0.22
Winstmarge	-1,286.548
Werknemers	30
EBITDA	35M -11M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+150.78% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-4.3M 142M
Vorige openingsprijs	1.37
Vorige sluitingsprijs	3.25

Nieuwssentiment

By Acuity

34%

66%

105 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

1.56 / 1.7 Steun & Weerstand

Cassava Sciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 dec 2025, 23:00 UTC

Acquisities, Fusies, Overnames

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5 dec 2025, 21:08 UTC

Acquisities, Fusies, Overnames

Meta Platforms Buys AI-Device Maker Limitless

5 dec 2025, 19:39 UTC

Belangrijke Marktbewegers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dec 2025, 19:17 UTC

Acquisities, Fusies, Overnames

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

7 dec 2025, 23:05 UTC

Marktinformatie

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7 dec 2025, 22:18 UTC

Marktinformatie

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6 dec 2025, 16:52 UTC

Acquisities, Fusies, Overnames

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 dec 2025, 10:30 UTC

Acquisities, Fusies, Overnames

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 dec 2025, 02:38 UTC

Acquisities, Fusies, Overnames

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

5 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dec 2025, 21:36 UTC

Marktinformatie

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dec 2025, 21:12 UTC

Marktinformatie

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dec 2025, 21:03 UTC

Marktinformatie

Winsten

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dec 2025, 21:01 UTC

Marktinformatie

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dec 2025, 20:42 UTC

Acquisities, Fusies, Overnames

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dec 2025, 20:01 UTC

Acquisities, Fusies, Overnames

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dec 2025, 19:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 dec 2025, 19:44 UTC

Marktinformatie

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dec 2025, 19:39 UTC

Marktinformatie

Silver Climbs to a New Record High -- Market Talk

5 dec 2025, 19:31 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:30 UTC

Marktinformatie

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dec 2025, 18:28 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:24 UTC

Acquisities, Fusies, Overnames

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Peer Vergelijking

Prijswijziging

Cassava Sciences Inc Prognose

Koersdoel

By TipRanks

150.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD 150.78%

Hoogste 8 USD

Laagste 8 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cassava Sciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Cassava Sciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.56 / 1.7Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

105 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.